2seventy bio, Inc. (TSVT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / September 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TSVT.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.
2seventy Bio stops enrolling patients in blood cancer therapy study
2seventy bio will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.
2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript
2seventy bio, Inc. (NASDAQ:TSVT ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs William Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmannn - Chief Medical Officer Conference Call Participants Daina Graybosch - Leerink Kelsey Goodwin - Guggenheim Securities Operator Good day, and thank you for standing by. Welcome to the 2Seventy Bio Second Quarter 2024 Earnings Conference Call.
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates
2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.83 per share a year ago.
Is the Options Market Predicting a Spike in 2seventy bio (TSVT) Stock?
Investors need to pay close attention to 2seventy bio (TSVT) stock based on the movements in the options market lately.
Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? What You Should Know
2seventy bio, Inc. (TSVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition
2seventy bio, Inc. focuses on Abecma, an FDA-approved CAR T cell therapy for multiple myeloma. TSVT's strategic realignment includes selling non-core assets to Regeneron and Novo Nordisk. Abecma shows favorable clinical data but faces strong competition from Carvykti.
